

表3 E M A により承認された配合剤

Medicine Name	Active Substance	Marketing Authorisation Holder	Authorisation date	Indication	
Brimica Genuair	aclidinium / formoterol fumarate dihydrate	Almirall S.A	19/11/2014	Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	慢性閉塞性肺疾患 (COPD)
Budesonide/Formoterol Teva	budesonide / formoterol fumarate dihydrate	Teva Pharma B.V.	19/11/2014	Budesonide/Formoterol Teva is indicated in adults 18 years of age and older only. AsthmaBudesonide/Formoterol Teva is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting 2 adrenoceptor agonist) is appropriate: in patients not adequately controlled with inhaled corticosteroids and as needed inhaled short-acting 2 adrenoceptor agonists.or in patients already adequately controlled on both inhaled corticosteroids and long-acting 2 adrenoceptor agonists. COPDSymptomatic treatment of patients with severe COPD (FEV1 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.	慢性閉塞性肺疾患 (COPD)
Budesonide/Formoterol Teva Pharma B.V.	budesonide / formoterol	Teva Pharma B.V.	19/11/2014	Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only. AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting 2 adrenoceptor agonist) is appropriate: in patients not adequately controlled with inhaled corticosteroids and as needed inhaled short-acting 2 adrenoceptor agonists. or in patients already adequately controlled on both inhaled corticosteroids and long-acting 2 adrenoceptor agonists.	喘息
Duaklir Genuair	aclidinium bromide / formoterol fumarate dihydrate	Almirall S.A	19/11/2014	Duaklir Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	慢性閉塞性肺疾患 (COPD)
Rezolsta	darunavir / cobicistat	Janssen-Cilag International N.V.	19/11/2014	Rezolsta, is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years or older. Genotypic testing should guide the use of Rezolsta	HIV1
Vylaer Spiromax	budesonide / formoterol fumarate dihydrate	Teva Pharma B.V.	19/11/2014	Vylaer Spiromax is indicated in adults 18 years of age and older only. AsthmaVylaer Spiromax is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting 2 adrenoceptor agonist) is appropriate: in patients not adequately controlled with inhaled corticosteroids and as needed inhaled short-acting 2 adrenoceptor agonists.or in patients already adequately controlled on both inhaled corticosteroids and long-acting 2 adrenoceptor agonists. COPDSymptomatic treatment of patients with severe COPD (FEV1 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.	喘息
Harvoni	sofosbuvir / ledipasvir	Gilead Sciences International Ltd	17/11/2014	Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adults.	慢性C型肝炎

Xultophy	insulin degludec / liraglutide	Novo Nordisk A/S	18/09/2014	Xultophy is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.	型糖尿病
Clopidogrel/Acetylsalicylic acid Teva	clopidogrel / acetylsalicylic acid	Teva Pharma B.V.	01/09/2014	Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed dose combination medicinal product for continuation of therapy in: NonST segment elevation acute coronary syndrome (unstable angina or nonQwave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy	アテローム血栓症
Triumeq	abacavir sulfate / dolutegravir sodium / lamivudine	ViiV Healthcare UK Limited	01/09/2014	Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see section 4.4). Abacavir should not be used in patients known to carry the HLA-B*5701 allele.	HIV
Simbrinza	brinzolamide / brimonidine tartrate	Alcon Laboratories (UK) Ltd	18/07/2014	Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.	開放隅角緑内障、高眼圧症
Anoro	umeclidinium bromide / vilanterol trifenate	Glaxo Group Ltd	08/05/2014	Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	慢性閉塞性肺疾患 (COPD)
Laventair	umeclidinium bromide / vilanterol	Glaxo Group Ltd	08/05/2014	Laventair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	慢性閉塞性肺疾患 (COPD)
Revinty Ellipta	fluticasone furoate / vilanterol trifenate	Glaxo Group Ltd	02/05/2014	Asthma Indication Revinty Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and as needed inhaled short acting beta2-agonists. COPD Indication Revinty Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite bronchodilator therapy.	喘息

BiResp Spiromax	budesonide / formoterol fumarate dihydrate	Teva Pharma B.V.	28/04/2014	<p>BiResp Spiromax is indicated in adults 18 years of age and older only.</p> <p>Asthma</p> <p>BiResp Spiromax is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting 2 adrenoceptor agonist) is appropriate: -in patients not adequately controlled with inhaled corticosteroids and as needed inhaled short-acting 2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting 2 adrenoceptor agonists.</p> <p>Chronic obstructive pulmonary disease</p> <p>Symptomatic treatment of patients with severe chronic obstructive pulmonary disease - COPD (FEV1 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.</p>	喘息
DuoResp Spiromax	budesonide / formoterol fumarate dihydrate	Teva Pharma B.V.	28/04/2014	<p>DuoResp Spiromax is indicated in adults 18 years of age and older only.</p> <p>Asthma</p> <p>DuoResp Spiromax is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting 2 adrenoceptor agonist) is appropriate: -in patients not adequately controlled with inhaled corticosteroids and as needed inhaled short-acting 2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting 2 adrenoceptor agonists.</p> <p>Chronic obstructive pulmonary disease</p> <p>Symptomatic treatment of patients with severe chronic obstructive pulmonary disease - COPD (FEV1 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.</p>	喘息
Ulnar Breezhaler	glycopyrronium bromide / indacaterol maleate	Novartis Europharm Ltd	23/04/2014	<p>Ulnar Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).</p>	慢性閉塞性肺疾患 (COPD)
Vokanamet	canagliflozin / metformin hydrochloride	Janssen-Cilag International N.V.	23/04/2014	<p>Vokanamet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:</p> <ul style="list-style-type: none"> - in patients not adequately controlled on their maximally tolerated doses of metformin alone - in patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5, and 5.1 for available data on different add on therapies) - in patients already being treated with the combination of canagliflozin and metformin as separate tablets 	型糖尿病

Xigduo	metformin hydrochloride / dapagliflozin propanediol monohydrate	Bristol-Myers Squibb/AstraZeneca EEIG	16/01/2014	Xigduo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone in combination with other glucose lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products/li in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.	型糖尿病
Fortacin	lidocaine / prilocaine	Plethora Solutions Limited	15/11/2013	Treatment of primary premature ejaculation in adult men.	早漏
Relvar Ellipta	fluticasone furoate / vilanterol	Glaxo Group Ltd	13/11/2013	Asthma Indication: Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and as needed inhaled short acting beta2-agonists. COPD Indication: Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite bronchodilator therapy.	喘息 / 慢性閉塞性肺疾患 (COPD)
(previously Levodopa/Carbidopa/Entacapone Sandoz)	levodopa / carbidopa / entacapone	Orion Corporation	11/11/2013	Corbilta is indicated for the treatment of adult patients with Parkinsons disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.	パーキンソン病
Evarrest	human fibrinogen / human thrombin	Omrix Biopharmaceuticals N. V.	25/09/2013	Evarrest is indicated in adults for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis.	手術時の止血
Incresync	alogliptin / pioglitazone	Takeda Pharma A/S	19/09/2013	Incresync is indicated as a second- or third-line treatment in adult patients aged 18years and older with type-2 diabetes mellitus: as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance; in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone. In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18years and older with type-2 diabetes mellitus already being treated with this combination. After initiation of therapy with Incresync, patients should be reviewed after threetosixmonths to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, Incresync should be discontinued. In light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of Incresync is maintained (see section4.4).	型糖尿病

Ultibro Breezhaler	indacaterol / glycopyrronium bromide	Novartis Europharm Ltd	19/09/2013	Ultibro Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	慢性閉塞性肺疾患 (COPD)
Vipdomet	alogliptin benzoate / metformin hydrochloride	Takeda Pharma A/S	19/09/2013	Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus: as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin; in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone; in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.	型糖尿病
Xoterna Breezhaler	indacaterol / glycopyrronium bromide	Novartis Europharm Ltd	19/09/2013	Xoterna Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	慢性閉塞性肺疾患 (COPD)
Cholib	fenofibrate / simvastatin	Abbott Healthcare Products Ltd.	26/08/2013	Cholib is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidaemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.	脂質代謝異常症
Voncento	human coagulation factor VIII / von Willebrand factor	CSL Behring GmbH	12/08/2013	Von Willebrand disease (VWD) Treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A (congenital factor-VIII deficiency) Prophylaxis and treatment of bleeding in patients with haemophilia A.	フォン・ウィルブランド病
Nuedexta	dextromethorphan / quinidine	Jenson Pharmaceutical Services Limited	24/06/2013	Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults (see section 4.4). Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.	仮性球情動
Stribild	elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate	Gilead Sciences International Limited	24/05/2013	Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.	HIV

Actelsar HCT	telmisartan / hydrochlorothiazide	Actavis Group hf	13/03/2013	<p>Treatment of essential hypertension.</p> <p>Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.</p> <p>Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.</p> <p>Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.</p>	本態性高血圧
Tolucombi	telmisartan / hydrochlorothiazide	Krka, d.d., Novo mesto	13/03/2013	<p>Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.</p>	高血圧
Ryzodeg	insulin degludec / insulin aspart	Novo Nordisk A/S	21/01/2013	Treatment of diabetes mellitus in adults	糖尿病
Jentadueto	linagliptin / metformin	Boehringer Ingelheim International GmbH	20/07/2012	<p>Treatment of adult patients with type-2 diabetes mellitus:</p> <p>Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.</p> <p>Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.</p>	型糖尿病
Eviplera	emtricitabine / rilpivirine hydrochloride /tenofovir disoproxil fumarate	Gilead Sciences International Ltd.	28/11/2011	<p>Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load 100,000 HIV-1 RNA copies/mL (see sections 4.2, 4.4 and 5.1). As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera (see sections 4.4 and 5.1).</p>	HIV1
Komboglyze	metformin hydrochloride /saxagliptin hydrochloride	AstraZeneca AB	24/11/2011	<p>Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.</p> <p>Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control.</p>	型糖尿病

Eurartesim	piperazine tetraphosphate / dihydroartemisinin	Sigma-Tau Industrie Farmaceutiche Riunite S.p.A	27/10/2011	Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more. Consideration should be given to official guidance on the appropriate use of antimalarial agents.	マラリア
Levodopa/Carbidopa/Entacapone Orion	levodopa / carbidopa / entacapone	Orion Corporation	24/08/2011	Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.	パーキンソン病
Zoely	norgestrel acetate / estradiol	Teva B.V.	27/07/2011	Oral contraception	避妊
Pravafenix	fenofibrate / pravastatin	Laboratoires SMB S.A.	14/04/2011	Pravafenix is indicated for the treatment of high-coronary-heart-disease (CHD)-risk adult patients with mixed dyslipidaemia characterised by high triglycerides and low HDL-cholesterol (C) levels whose LDL-C levels are adequately controlled while on a treatment with pravastatin-40-mg monotherapy.	冠動脈疾患
Rasilamlo	aliskiren / amlodipine	Novartis Europharm Ltd.	14/04/2011	Rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.	本態性高血圧
Teysuno	tegafur / gimeracil / oteracil	Nordic Group BV	14/03/2011	Teysuno is indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin.	進行性胃がん
Ifirmacombi	irbesartan / hydrochlorothiazide	Krka, d.d., Novo mesto	04/03/2011	Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	本態性高血圧
Lamivudine/Zidovudine Teva	lamivudine / zidovudine	Teva Pharma B.V.	28/02/2011	Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.	HIV
Twynsta	telmisartan / amlodipine	Boehringer Ingelheim International GmbH	07/10/2010	Treatment of essential hypertension in adults: Add-on therapy Twynsta is indicated in adults whose blood pressure is not adequately controlled on amlodipine. Replacement therapy Adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses.	本態性高血圧
DuoCover	clopidogrel / acetylsalicylic acid	Sanofi-aventis groupe	15/03/2010	DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoCover is a fixed-dose combination medicinal product for continuation of therapy in: non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention; ST-segment-elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.	アテローム血栓症

DuoPlavin	clopidogrel / acetylsalicylic acid	Sanofi Pharma Bristol-Myers Squibb SNC	15/03/2010	DuoPlavin is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in: non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention; ST-segment-elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.	アテローム血栓症
Ristfor	sitagliptin / metformin hydrochloride	Merck Sharp & Dohme Ltd.	15/03/2010	For patients with type-2 diabetes mellitus: Ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. Ristfor is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. Ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated-receptor-gamma (PPAR) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist. Ristfor is also indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	型糖尿病
Irbesartan/Hydrochlorothiazide Teva	irbesartan / hydrochlorothiazide	Teva Pharma B.V.	26/11/2009	Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	本態性高血圧
Copalia HCT	amlodipine / valsartan / hydrochlorothiazide	Novartis Europharm Ltd.	04/11/2009	Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.	本態性高血圧
Dafiro HCT	amlodipine besylate / valsartan / hydrochlorothiazide	Novartis Europharm Ltd.	04/11/2009	Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.	本態性高血圧
Exforge HCT	amlodipine besylate / valsartan / hydrochlorothiazide	Novartis Europharm Limited	16/10/2009	Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.	本態性高血圧

Vantavo (previously Alendronate sodium and colecalfiferol, MSD)	alendronic acid / colecalfiferol	Merck Sharp & Dohme Ltd.	16/10/2009	Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Vantavo reduces the risk of vertebral and hip fractures. Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin-D supplementation and are at risk of vitamin-D insufficiency. Vantavo reduces the risk of vertebral and hip fractures.	閉経後骨粗しょう症
Rasilez HCT	aliskiren / hydrochlorothiazide	Novartis Europharm Ltd.	16/01/2009	Treatment of essential hypertension in adults. Rasilez HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone. Rasilez HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.	本態性高血圧
Icandra (previously Vildagliptin / metformin hydrochloride Novartis)	vildagliptin / metformin hydrochloride	Novartis Europharm Ltd.	01/12/2008	Icandra is indicated in the treatment of type-2 diabetes mellitus: Icandra is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. Icandra is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea. Icandra is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.	型糖尿病
Zomarist	vildagliptin / metformin hydrochloride	Novartis Europharm Ltd.	01/12/2008	Zomarist is indicated in the treatment of type-2 diabetes mellitus: Zomarist is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. Zomarist is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea. Zomarist is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.	型糖尿病
Azarga	brinzolamide / timolol	Alcon Laboratories (UK) Ltd	25/11/2008	Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.	開放隅角緑内障、高眼圧症
Evicel	human fibrinogen / human thrombin	Omrrix Biopharmaceuticals S.A.	06/10/2008	Evicel is used as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. Evicel is also indicated as suture support for haemostasis in vascular surgery.	手術時の止血

Effcib	sitagliptin / metformin hydrochloride	Merck Sharp & Dohme Ltd.	16/07/2008	<p>For patients with type-2 diabetes mellitus: Effcib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. Effcib is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. Effcib is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist. Effcib is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.</p>	型糖尿病
Janumet	sitagliptin / metformin hydrochloride	Merck Sharp & Dohme Ltd.	16/07/2008	<p>For patients with type-2 diabetes mellitus: Janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. Janumet is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. Janumet is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist. Janumet is also indicated as add on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.</p>	型糖尿病
Velmetia	sitagliptin / metformin hydrochloride	Merck Sharp & Dohme Ltd.	16/07/2008	<p>For patients with type-2 diabetes mellitus: Velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. Velmetia is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. Velmetia is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist. Velmetia is also indicated as add on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.</p>	型糖尿病